News
The study of Clostridium difficile infection (CDI) continues to reveal intricate details of its pathogenesis, epidemiology and potential novel therapies. Research has elucidated how the bacterium ...
Clostridium difficile infection (CDI) is considered to be the main cause of bacterial infectious diarrhea in nosocomial settings. Since the beginning of the new century a continuous rise in the ...
A group of gut bacteria successfully hindered recurrent Clostridium difficile infection in mice, offering alternative therapeutic strategies to antibiotics and fecal transplant.
Scientists have created a probiotic to restore bile salt metabolism found in the gastrointestinal tract, to counter the onset and effects of Clostridium Difficile Infection (CDI).
In animal models, this first mRNA-LNP C. difficile vaccine was found to protect against C. difficile first-time infections and relapsing infections by inducing a robust immune response, promote ...
Many people who have C. diff have recurrent infections, and the symptoms of a recurrence are broadly similar to those of the original infection. Learn more.
The stubborn superbug Clostridium difficile, or C. diff, may have met its match. A esearcher is reporting the first well-controlled study to demonstrate the effectiveness of a new medicine for ...
One in 6 people who got clostridium difficile (C. diff) will get a second infection within a few weeks of their first one. Read more to learn how to prevent the spread and reinfection.
But because fecal transplant addresses the root cause of the infection, researchers suspected it might be effective as a front-line treatment for C. difficile.
A synthetic microbiome therapy, tested in mice, protects against severe symptoms of a gut infection that is notoriously difficult-to-treat and potentially life threatening in humans, according to ...
Nonpharmacological strategies Infection prevention is at the forefront of efforts to reduce all HAIs, although it is especially prominent in minimizing C. difficile transmission.
Ferring Pharmaceuticals’ biotherapeutic passed an FDA committee vote for C. difficile despite some skepticism from a handful of members.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results